Our funds
The fund

Fondita Healthcare is an actively managed, global healthcare fund. In line with the Article 9 sustainability rating, the fund’s social sustainability objective is to invest in companies that promote health and well-being, as well as access to healthcare and equality in their own business operations.

Healthcare

The fund invests in companies that address current and unmet medical needs and provide access to medicine and medical care. This is achieved by investing in companies active in innovation, production and distribution of medicines and healthcare equipment, tools and supplies as well as diagnostics and healthcare services. Operationally, the companies are to act in a socially and environmentally responsible way.

Healthcare is an incredibly interesting, structurally growing sector and one of the three megatrends that Fondita’s thematic funds invest in.

Demographic changes with an ageing population, as well as increased welfare, translate into growing demand for healthcare. Innovation and technological advances improve care and deliver new products to fulfil current and unmet demand fueling the sector’s growth.

Sustainability
Read more about the fund’s sustainability principles:
Fund facts

31.3.2025

Fund size (M€)
24,3
ISIN (A)
FI4000321088
ISIN (B)
FI4000321096
Currency
EUR
Management fee
2,00 % p.a.
Risk indicator
4/7
SFDR Classification
Article 9
The fund manager's comment
March was a tough month for global equity markets. The world index lost 8.1% and was weighed down by chaotic US tariff announcements with reciprocal reactions from trade partners, recession fears, and geopolitical uncertainty which all dampened confidence. All MSCI World sectors, except Energy, finished in the red. Healthcare was affected by tariff uncertainty as well as s...
Top holdings
Eli Lilly (US)
8,3 %
Unitedhealth Group (US)
6,4 %
Medtronic (US)
5,8 %
Boston Scientific (US)
5,2 %
Stryker (US)
4,3 %
USA
50 %
Switzerland
12 %
Denmark
10 %
Sweden
10 %
Belgium
5 %
Return
1 month
-8,1 %
3 months
-4,5 %
6 months
-9,3 %
YTD
-4,5 %
1 year
-4,1 %
3 years
-7,1 %
5 years
38,3 %
since launch (14.6.2018)
45,9 %
since launch p.a.
5,7 %
Sector division
Pharma
58 %
Equipment
40 %
Cash
1 %
Top 10 holdings
Eli Lilly (US)
8,3 %
Unitedhealth Group (US)
6,4 %
Medtronic (US)
5,8 %
Boston Scientific (US)
5,2 %
Stryker (US)
4,3 %
AstraZeneca (US)
4,1 %
Hologic (US)
3,9 %
Jazz Pharmaceuticals (US)
3,8 %
Merck & Co (US)
3,8 %
Siegfried Holding (CH)
3,5 %
Country division
USA
50 %
Switzerland
12 %
Denmark
10 %
Sweden
10 %
Belgium
5 %
Germany
5 %
Other
8 %
Currency exposure
USD
50 %
EUR
16 %
CHF
12 %
DKK
10 %
SEK
10 %
GBP
2 %
Fees
TER
2,00 %
Subscription fee
0,00 %
Redemption fee
0,00 %

Total client relationship allow for changes in tariff rate.

Documents

FUND INFORMATION
KID
PAI Statements
Fund rules
KID DE
KID I DE
Prospectus
REPORTS
Monthly report
Annual report
Semi-annual report
SUSTAINABILITY DOCUMENTS
ESG Report
Shared sustainability documents
Sustainability-related disclosures

This is marketing communication. The past performance of the investment fund does not provide any guarantee of future results. Read the fund prospectus and KID (Key Information Document) before making any investment decisions. The fund prospectus and KID are available on English, Finnish and Swedish at our website.

Our funds
Latest news
Is it time for active Equity Funds again? 

Trump’s tariff threats have been unsettling the markets for a couple of months. However, the country-specific tariffs announced last week exceeded even the ... Read more

Our Portfolio Managers on the road in March

Kenneth Blomqvist and Janna Haahtela attended two investor conferences in March, meeting with 33 companies, 19 of which are current portfolio holdings. ... Read more

This page was last updated

Web design: Wikström Media
Fondita online Fondita
online